Femtobiomed Inc. Logo

Femtobiomed Inc.

Develops a non-viral intracellular delivery platform for cell and gene therapy.

327610 | KO

Overview

Corporate Details

ISIN(s):
KR7327610002
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로 700D동 510호(야탑동, 분당테크노파크), 성남시

Description

Femtobiomed Inc. is a cell engineering company that develops technologies for the cell and gene therapy industry. The company's core offering is the CellShot® platform, a proprietary, non-viral intracellular delivery system. This platform utilizes a patented technology known as 'Partitioned Flow Transfection,' which functions as a three-dimensional nanoinjection system for the direct, cargo-free delivery of biomolecules into individual cells. The technology is designed to support the discovery and development of advanced therapeutics, including anti-cancer treatments, for the healthcare and research sectors. Femtobiomed aims to pioneer non-viral cell engineering to accelerate the creation of novel cell therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-19 00:00
사업보고서 (2024.12)
Korean 973.8 KB
2025-03-18 00:00
감사보고서제출
Korean 10.6 KB
2025-03-07 00:00
주주총회소집공고
Korean 78.8 KB
2025-02-24 00:00
주주총회소집결의
Korean 12.6 KB
2025-02-14 00:00
주식등의대량보유상황보고서(일반)
Korean 114.9 KB
2025-01-07 00:00
주식등의대량보유상황보고서(일반)
Korean 109.9 KB
2024-12-13 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2024-12-02 00:00
대표이사변경
Korean 8.6 KB
2024-10-29 00:00
기업설명회(IR)개최결과
Korean 6.7 KB
2024-10-14 00:00
기업설명회(IR)개최
Korean 6.9 KB
2024-05-08 00:00
주식등의대량보유상황보고서(약식)
Korean 53.9 KB
2024-04-23 00:00
증권발행결과(자율공시) (제3자배정 유상증자)
Korean 5.2 KB
2024-04-08 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 50.0 KB
2024-04-04 00:00
주식등의대량보유상황보고서(일반)
Korean 103.6 KB
2024-03-28 00:00
정기주주총회결과
Korean 19.8 KB

Automate Your Workflow. Get a real-time feed of all Femtobiomed Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Femtobiomed Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Femtobiomed Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.